Τίτλος:
Hematological findings and complications of COVID-19
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
COVID-19 is a systemic infection with a significant impact on the hematopoietic system and hemostasis. Lymphopenia may be considered as a cardinal laboratory finding, with prognostic potential. Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. During the disease course, longitudinal evaluation of lymphocyte count dynamics and inflammatory indices, including LDH, CRP and IL-6 may help to identify cases with dismal prognosis and prompt intervention in order to improve outcomes. Biomarkers, such high serum procalcitonin and ferritin have also emerged as poor prognostic factors. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-Dimer levels are consistently reported, whereas their gradual increase during disease course is particularly associated with disease worsening. Other coagulation abnormalities such as PT and aPTT prolongation, fibrin degradation products increase, with severe thrombocytopenia lead to life-threatening disseminated intravascular coagulation (DIC), which necessitates continuous vigilance and prompt intervention. So, COVID-19 infected patients, whether hospitalized or ambulatory, are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with low molecular weight heparin is highly recommended. Last but not least, the need for assuring blood donations during the pandemic is also highlighted. © 2020 Wiley Periodicals, Inc.
Συγγραφείς:
Terpos, E.
Ntanasis-Stathopoulos, I.
Elalamy, I.
Kastritis, E.
Sergentanis, T.N.
Politou, M.
Psaltopoulou, T.
Gerotziafas, G.
Dimopoulos, M.A.
Περιοδικό:
American Journal of Hematology
Εκδότης:
Wiley-Liss, Inc.
Λέξεις-κλειδιά:
biological marker; C reactive protein; ferritin; procalcitonin; anticoagulant agent; biological marker; C reactive protein; cytokine; ferritin; fibrin degradation product; fibrin fragment D, adverse event; biochemistry; blood cell count; blood clotting disorder; clinical feature; coronavirus disease 2019; epidemic; hematology; hematopoietic stem cell; human; infection risk; leukocytosis; leukopenia; lymphocytopenia; mortality risk; platelet count; platelet lymphocyte ratio; priority journal; prognosis; Review; risk factor; Severe acute respiratory syndrome coronavirus 2; thrombocytopenia; Betacoronavirus; blood; blood clotting test; blood donor; complication; Coronavirus infection; cytokine release syndrome; disseminated intravascular clotting; early diagnosis; laboratory technique; lymphocytopenia; meta analysis (topic); pandemic; risk; thrombophilia; venous thromboembolism; virus pneumonia, Anticoagulants; Betacoronavirus; Biomarkers; Blood Coagulation Tests; Blood Donors; C-Reactive Protein; Clinical Laboratory Techniques; Coronavirus Infections; Cytokine Release Syndrome; Cytokines; Disseminated Intravascular Coagulation; Early Diagnosis; Ferritins; Fibrin Fibrinogen Degradation Products; Humans; Lymphopenia; Meta-Analysis as Topic; Pandemics; Pneumonia, Viral; Risk; Thrombophilia; Venous Thromboembolism
